KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Receivables: 2017-2025

Historic Change in Receivables for BeOne Medicines (ONC) over the last 8 years, with Sep 2025 value amounting to $93.9 million.

  • BeOne Medicines' Change in Receivables rose 214.68% to $93.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.0 million, marking a year-over-year increase of 17.89%. This contributed to the annual value of $329.4 million for FY2024, which is 74.95% up from last year.
  • Latest data reveals that BeOne Medicines reported Change in Receivables of $93.9 million as of Q3 2025, which was up 126.31% from $41.5 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Change in Receivables high stood at $353.8 million for Q4 2021, and its period low was -$292.6 million during Q1 2022.
  • Its 3-year average for Change in Receivables is $62.3 million, with a median of $44.8 million in 2023.
  • As far as peak fluctuations go, BeOne Medicines' Change in Receivables soared by 263,963.43% in 2021, and later plummeted by 1,336.70% in 2022.
  • Quarterly analysis of 5 years shows BeOne Medicines' Change in Receivables stood at $353.8 million in 2021, then tumbled by 105.48% to -$19.4 million in 2022, then spiked by 330.96% to $44.8 million in 2023, then surged by 180.61% to $125.7 million in 2024, then surged by 214.68% to $93.9 million in 2025.
  • Its Change in Receivables was $93.9 million in Q3 2025, compared to $41.5 million in Q2 2025 and $31.9 million in Q1 2025.